Mar 12th 2013 - Edison Investment Research today published a report on quickview entitled "Greer Is Good?". In summary, the report says:
The acquisition of Greer by Stallergenes’ largest shareholder opens the prospect of a US commercial partnership between the two companies. Greer is a leading player in the US allergy immunotherapy market and a tie-up with Stallergenes could provide a ready-made entry into the US. A deal is being evaluated and an update is expected in Q213. Progress with the allergy tablets in the EU, US and Japan remains a key value driver for the shares. US launch of Oralair is expected in Q114.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »